LATAM Pharmaceutical Products and CMO Market is Anticipated to Show the Robust Growth During 2016 - 2024

The highly fragmented competitive landscape of the Latin America pharmaceutical and contract manufacturing organizations (CMO) market features a large number of small and large vendors operating amidst immense competition in terms of cost and variety of services delivered, observes a recent report by Transparency Market Research. While at one point pharmaceutical companies are struggling to gain sustainable returns owing to rising cost pressures, the increased inclination towards outsourcing a number of processes is leading to vast growth opportunities for CMOs.
With the top five vendors in the market, namely Bayer AG, BASF SE, Novartis AG, Pfizer, Inc., and Merck & Co., Inc., collectively accounting for a mere 23% of overall market in 2015, it is obvious that domestic vendors, chiefly producing generics, account for a massive chunk of the overall market. In the next few years as well, pharmaceutical companies producing generics are expected to hold prominent positions in the market and in a bid to focus more on core competencies and internal R&D activities, international companies will create high demand for CMOs.
This 156 page report gives readers a comprehensive overview of the pharmaceutical products and CMO market. Browse through 14 data tables and 43 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/latin-america-pharmaceutical-products-cmo-market.html
Transparency Market Research states that the LATAM pharmaceutical products and CMO market will exhibit a healthy 9.3% CAGR over the period between 2016 and 2024, rising from a valuation of US$127.9 bn in 2015 to US$286.2 bn 2024.
Finished Dosage Form to Retain Dominance in terms of Pharmaceutical Products
On the basis of product variety, the segment of finished dosage form presently leads the LATAM pharmaceutical products. The segment accounted for over 85% of the overall market in 2015 and is expected to retain its dominant position in the market over the report’s forecast period. However, the API and ingredients segment will emerge as the segment with the most promising rate of growth in the LATAM pharmaceutical products market, registering a nearly 10% CAGR over the report’s forecast period. The Latin America CMO market, on the other hand, was dominated by the API and ingredients segments. The segment of finished dosage form is also expected to gain high traction in the Latin America CMO market over the next few years.
Geographically, Brazil led the LATAM market for pharmaceutical products as well as CMO, chiefly owing to the rising number CMOs in the country and an increased focus of pharmaceutical companies on research activities. On the other hand, the pharmaceutical products and CMO market in Argentina is expected to exhibit a remarkable CAGR of 11.6% over the forecast period.
Improving Regulatory Framework to Encourage Foreign Investment
In the past few years, the regulatory framework of countries in Latin America such as Mexico, Brazil, Colombia, and Peru has significantly improved, leading to the creation of a more open business environment. This has attracted several multinational pharmaceutical companies to the region, which continue to invest in research and development activities in the region. Swift drug approvals, a relatively naïve pharmaceutical industry, and an inclination to free good in the region also make it a prime investment destination for many pharmaceutical companies wanting to expand their geographical expanse.
For CMOs, Latin America is increasingly becoming a highly lucrative region owing to patent expiries of several blockbuster drugs. The rise in the number of generic drug manufacturers in this scenario is highly conducive for contract manufacturers. Moreover, international pharmaceutical vendors approach CMOs to achieve the benefits of low-cost drug production while being able to concentrate on research and development of novel drug compounds with the help of in-house resources.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving pharmaceutical products and CMO market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14009
Limited Reimbursement Policies to Hamper Growth
The pharmaceutical industry in most Latin America countries lacks a well-established reimbursement structure and very limited reimbursement is offered outside hospital settings. Reimbursement is also highly restricted and is provided mostly to the poor, is based on health technology assessment (HTA), and to generic drugs. The scenario is expected to have a notable negative impact on the overall development of the LATAM pharmaceutical products and CMO market in the next few years.
This review of the Latin America pharmaceutical products and CMO market is based on a recent report published by Transparency Market Research, titled “Pharmaceutical Products and CMO Market - LATAM Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Veterinary Vaccines Market Segment Forecasts up to 2024, Research Reports

The global market for veterinary vaccines features an exceedingly consolidated competitive and vendor landscape, with the top three companies, namely Zoetis, Inc., Merck & Co., and Sanofi Aventis, collectively accounting for nearly half the market in 2015, observes a recent report by Transparency Market Research. The vast funds required for research and development in the field of vaccines have made it possible for a small number of small-scale companies to gain a stronghold in the global market. In 2015, small-scale companies accounted for a mere 30% of the overall market.
Transparency Market Research predicts that the global veterinary vaccines market will exhibit a nearly 7% CAGR from 2016 through 2024 and rise from US$6,271.8 mn in 2015 to US$11,403.6 mn by 2024.
This 185 page report gives readers a comprehensive overview of the veterinary vaccines market. Browse through 24 data tables and 50 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/veterinary-vaccines-market.html
Live Attenuated Vaccines to Continue to Dominate Global Sales
In terms of vaccine technology, the segments of live attenuated and inactivated vaccines collectively accounted for a share of nearly 80% in the global veterinary vaccines market. Used largely for companion animals, live attenuated vaccines individually held a nearly 44% of the overall market in 2015. These vaccines are produced in bulk owing to low cost of production. Over the report’s forecast period, the live attenuated vaccines technologies will continue to remain the dominant contributor to the revenue of the global veterinary vaccines market.
In terms of animal type, the segment of canine vaccines accounted for the dominant 52.7% of the global market in 2015. The segment is expected to exhibit a remarkable 8.6% CAGR from 2016 through 2024 and retain its dominant position in the global market. Geographically, North America led the market in 2015, accounting for a more than 44% of the global market.
Increased uptake of Animal Protein in Developing Economies Key to Market Growth
Animal products such as pork, beef, milk, chicken, and eggs contribute nearly 40% to the GDPs of agrarian economies. The market for these livestock-source foods generated revenues worth US$600 bn in 2015 and their demand is expected to expand at a significant pace across the globe in the next few years, especially across developing economies due to rising disposable incomes and increased focus on nutrition and healthcare. China, for instance, accounts for over half of the world’s total swine meat consumed on an annual basis. As the demand for animal-source food products increases, the focus on animal health and wellness will rise across the globe and will subsequently lead to a significant rise in the demand for veterinary vaccines.
Stringent Approval Policies and Short Exclusivity Periods to Arrest Market Growth
Product exclusivity periods of spans as short as three to five years are one of the key challenges faced by companies operating in the animal health care industry. The veterinary vaccines market also bears the brunt of this issue and the inevitable introduction of generics and over-the-counter products post patent expiration mars the profitability of companies who have spent vast funds on R&D to develop a new vaccine.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving veterinary vaccines market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=215
Apart from this, the overall growth prospects of the global veterinary vaccines market are also hampered due to the high dependence of market players on government channels for distribution. In India, for instance, the central and state governments purchase foot and mouth disease vaccines in bulk and supply them in different parts of the country. Bulk purchases often translate into reduced profits for the manufacturers and hamper the profitability of the entire global veterinary vaccines market.
This review of the market is based on a recent market research report by Transparency Market Research, titled “Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016–2024.” 

Biologics Market: North America Prominent Market; Expanding Scope of Biologics Makes Asia Pacific Lucrative

The global biologics market features an intensely fragmented and competitive landscape with the presence of several regional players competing against some of the global most prominent pharmaceutical companies, observes Transparency Market Research (TMR). Some of the leading players operating in the global biologics market are Novartis International AG, GlaxoSmithKline plc, AstraZenca, Bristol-Myers Squibb, and Eli Lilly and Company. A large number of companies are opting for partnerships and collaborations to expedite their drug development activities.
Big players are investing substantial amounts in mergers and acquisitions to strengthen their market presence and to expand their product portfolio. Furthermore, leading players are launching novel biologic therapies approved by the U.S. FDA to consolidate their shares in major regions.
This 179 page report gives readers a comprehensive overview of the biologics market. Browse through 18 data tables and 101 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-biologics-market.html
In recent years, top companies in the biologics market have focused their efforts on several co-development and licensing deals with emerging biotechnology players to discover new biologic drugs. For instance, Novartis announced in May, 2017 that it is mulling an option to license the mid-stage drug development by Conatus Pharmaceuticals for Nonalcoholic Steatohepatitis (NASH), popularly known as non-alcoholic fatty liver disease. The global pharmaceutical company has paid a whopping amount of $50 million upfront to Conatus as part of its deal for emricasan drug in December, 2016. The company is expected to receive a whopping sum of $7 million payment from Novartis later this year. Another big player Amgen has recently announced to ink a partnership deal with Elasmogen Ltd. and Feldan in developing intracellular biologics. Such developments are likely to intensify the competition in the market in the coming years.
The global market for biologics is projected to rise at 10.9% CAGR from 2016 to 2024. Expanding at a steady rate, the opportunities in the market is projected to reach US$479, 752 mn by the end of the forecast period.
Monoclonal Antibodies Segment Gains Prominence
Geographically, the major regional markets are Europe, North America, Latin America, the Middle East and Africa (MEA), and Asia Pacific; of these, North America currently dominates the global market. This regional market is projected to occupy a significant revenue share of over 40% by the end of the forecast period. The growth of the North America market is driven by substantial R&D spending on developing novel biologics and numerous collaboration activities in advanced nations.
Based on product type, the global biologics market is segmented into cell therapy, monoclonal antibodies, vaccines, recombinant hormones/proteins, and gene therapy. Amongst these, monoclonal antibodies is projected to be the leading product segment. The substantial growth in the segment is driven by the soaring demand for novel personalized and targeted therapies in various regions. This segment is projected to expand at a CAGR of 11.9% during the forecast period.
Growing R&D Investments to Boost Biologics Development
The growing patient base due to rising prevalence of chronic and rare diseases has stimulated the demand for novel therapies. The promise of lucrative returns due to the premium pricing of several biologic drugs has triggered investments by large players in the global biologics market. Extensive R&D activities in various developing and developed regions are further expected to catalyze the biologics market. Furthermore, intensifying pharmacological norms related to constant monitoring of the safety of these biologics among a wide population base during the post-marketing period augurs well for the biologics market growth.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving biologics market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15509
However, compared to traditional drugs, the development of biologics calls for substantial investment in drug pipeline, which is a key factor hampering the biologics market to an extent. The total time required for clinical trials and drug approvals, especially for rare diseases, may further dissuade many small companies to invest in the market. Nevertheless, the increasing number of favorable regulations for the approval of biologics has accelerated biologics development process, thereby boosting the market. In addition, several international pharmaceutical companies are opening their biologics production facilities in various emerging markets, such as in Asia Pacific, to bring down operational and production cost. This is expected to positively impact the growth of the biologics drug market.
The study presented here is based on a report by Transparency Market Research (TMR) titled, “Biologics Market (Product - Monoclonal Antibodies, Vaccines, Cell Therapy, Recombinant Hormones/Proteins, and Gene Therapy; Application - Infectious Diseases, Oncology, Immunology, and Autoimmune Diseases) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Viral Conjunctivitis Pipeline Drugs Market To See Good Times Ahead

The manufacturers of viral conjunctivitis pipeline drugs market are undertaking extensive research studies to fulfill the demand for targeted drugs that can efficiently and accurately treat conjunctivitis. Players are also striving hard to develop viral conjunctivitis detection tests that are affordable, Transparency Market Research observes in a new study. Companies in the market are strengthening their research and development power by participating in partnerships and agreements, which is helping them power up for expanding their product portfolios. It is estimated that the drug with less toxicity and irritation properties will outperform all others in the viral conjunctivitis pipeline drugs market. Players in the market need to develop innovative products and upgrade existing ones at reasonable price to ensure competitive edge.
This 70 page report gives readers a comprehensive overview of the viral conjunctivitis pipeline drugs market. Browse through 7 data tables and 17 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/viral-conjunctivitis-pipeline-drugs-market.html
According to TMR, the global viral conjunctivitis pipeline drugs market is expected to witness a massive growth in the market, expanding at a stupendous 69.60% CAGR from 2020 to 2023. The market is expected to reach an evaluation of US$462.4 mn by 2023. By drug type, FST-100 is estimated to hold the largest share in the market by 2020, expanding at a CAGR of 27.40% from 2020 to 2023. However, APD-209 segment is expected to expand at the fastest rate, displaying CAGR of 55.0% between 2020 and 2023.
Availability of Efficient Detection Tests to Drive U.S. Market
On the basis of geography, North America is expected to lead in the market with the U.S. proving to be the most promising market for viral conjunctivitis drugs. The U.S. viral conjunctivitis pipeline drugs market is expected to be worth US$91.1 mn by 2020. The increasing awareness and availability of conjunctivitis detection tests that are effective are some of the reasons behind the growth of the U.S. conjunctivitis pipeline drugs market. Brazil is expected to be the second most lucrative market for viral conjunctivitis drugs on account of the launch of FST-100. Germany and the U.K. are expected to follow suit.
High Spending on Medicine Research to Bode Well for Viral Conjunctivitis Pipeline Drugs Market
As per research studies, around 6 mn people are suffering from acute conjunctivitis every year. The prevalence of conjunctivitis is increasing across nations in Europe, Asia Pacific, and North America, which is boosting the growth of the conjunctivitis pipeline drugs market. In the U.S., the emergence of AdenoPlus, which is a conjunctivitis detection test, has led to a positive development in the field, despite its high cost. The high expenditure on medicine research and healthcare is ensuring the growth of this market in developed nations.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving viral conjunctivitis pipeline drugs market during 2020 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12251
Shortage of Efficient Drugs to Impede Market’s Growth
Although the global conjunctivitis pipeline drugs market is witnessing an exponential growth, the patient pool is much larger and thus, there is a shortage of efficient drugs. There are unmet needs to be fulfilled for the patient population across nations. This in turn is expected to challenge the global conjunctivitis pipeline drugs market. The absence of any drug in the late stage pipeline is also a challenge, hampering the growth of the conjunctivitis pipeline drugs market. The presence of pipeline drugs such as FST-100 and APD-209 in the second phase of clinical trials is a bright opportunity for growth in the market. However, many other drugs for the treatment of conjunctivitis are still in the preclinical trials stage.
This study is based on the findings of a TMR report titled “Viral Conjunctivitis Pipeline Drugs Market (Drug Type - FST-100 and APD-209) - Global Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023.”

Hospital Pharmaceuticals Market Outlook and Forecast up to 2023

The leading players in the global hospital pharmaceutical market held a share of 22.5% in 2014. The players, Novartis, Pfizer, Sanofi, Roche, and Merck & Co., have remained dominant in the overall market due to their well-planned, strategic partnerships with small and medium-sized local players to strengthen their pipeline. Furthermore, the development of new drugs will also help the companies remain relevant in the intense competition. “Shifting focus towards Asia Pacific will prove to be beneficial to the players in the global market as the region is undergoing a positive economic change that is characterized with rising disposable incomes and improving infrastructure,” states the lead author of the research report.
This 192 page report gives readers a comprehensive overview of the hospital pharmaceuticals market. Browse through 12 data tables and 43 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html
Rising Number of Heart Patients Catapults Cardiovascular Segment to Forefront
According to the research report, the opportunity in the global hospital pharmaceuticals market is expected to be worth US$280.3 bn by the end of 2023 from US$197.3 bn in 2014. The global market is anticipated to progress at a CAGR of 3.9% during the forecast period of 2015 to 2023. The global market is likely to witness North America in the lead as the regional market is anticipated to expand at a CAGR of 3.4% during the forecast years. The recovery of the pharmaceutical industry in North America and the rising per capita spending on health care are expected to boost the regional hospital pharmaceuticals market in the coming few years. Amongst the various types of indications being treated by hospital pharmaceuticals, the cardiovascular segment is anticipated to gain notable traction in the next few years. The high prevalence of cardiovascular diseases is expected to boost this segment at a 0.8% CAGR during the forecast years.
Demand for Hospital Pharmaceuticals Soars as Patents Cliff
The growing incidents of accidents, traumas, and other emergencies have spiked the demand for specialty drugs in hospitals across the globe. Additionally, growing prevalence of pneumonia, malaria, AIDS, and tuberculosis have also triggered a significant uptake of hospital pharmaceuticals in recent years. The growing number of cancer cases have also accelerated the consumption of hospital pharmaceuticals. The oncology segment includes drugs such as alkylating agents, anti-metabolites, hormonal agents, and immunomodulating agents. These pharmaceuticals are used for treating lung, breast, colorectal, and prostate cancer. A sudden jump in the number patients suffering from cardiovascular diseases has also augmented the demand for related hospital pharmaceuticals. All in all, growing cases of chronic conditions are responsible to the rising consumption of these pharmaceuticals
The looming patent expiry for blockbuster drugs such as Lyrica (pregabalin), Nucynta (Tapentadol), Avastin (bevacizumab), and Alimta (Pemetrexed) has created a promising ground for the entry of generic drugs. This emerging trend is expected to improve the affordability of several hospital pharmaceuticals for the low-income groups and thus result in increased spending. The high adoption rate of telemedicine technology across the healthcare sector to reach out of patients in remote locations has also proved to be a critical growth factor for the global hospital pharmaceutical market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving hospital pharmaceuticals market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3535
Preference for Home Care Reduces Chances for Sale of Hospital Pharmaceuticals
Though a perspective suggests that patent expirations could benefit the overall market, it is also logical to conclude that patent cliff could result in reduced sales and thus lesser revenues for certain drugs. Significant patent expirations are likely to hamper the global market during the forecast period. Furthermore, growing preference for home care has reduced hospital visits to a large degree, which has made a noticeable negative impact on the demand for hospital pharmaceutical in recent years.
The review is based on Transparency Market Research’s report, titled “Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”

Nebulizers Market grows with increasing prevalence of asthma, cystic fibrosis, and COPD

The influx of enterprises has rendered the India nebulizers market highly fragmented. Despite the intense competition prevailing among the companies, CareFusion, Omron Healthcare, and Philips Healthcare emerged dominant holding approximately 52% of the market in 2014. Looking forward, the market players are forecast to aggressively invest in research and development to innovate products, subsequently strengthening their position in the India nebulizers market.
The strategies adopted by the players have been significantly contributing to the market’s growth. According to Transparency Market Research (TMR), the India nebulizers market is projected to exhibit an impressive CAGR of 25.8% between 2015 and 2023. Expanding at this pace, the market is projected to reach INR4.7 bn by the end of 2023, from a valuation of INR575.6 mn in 2014.
This 93 page report gives readers a comprehensive overview of the nebulizers market. Browse through 5 data tables and 18 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/india-nebulizers-market.html
North Zone to Represent Higher Consumption of Nebulizers in India
Presently, the north zone exhibits comparatively higher consumption than any other zones in India. As the prevalence of chronic obstructive pulmonary disorder (COPD) is skyrocketed due to the cold climate and the increasing level of pollution. The incidence of the ailment is not likely to diminish any time soon. Considering the efficiency of nebulizers in curing such ailments, the demand for the same is poised to surge in the zone at 27.5% CAGR during the forecast period. Based on product type, the pneumatic nebulizer segment currently hold dominance in the India nebulizers market.
Rising Adoption of Nebulizers Expected as India Witnesses Increasing Incidence of Respiratory Disorders
As per the World Health Organization (WHO), deaths due to lung ailment in India are in continuous rise. Furthermore, in the last few years the prevalence of acute respiratory disorders such as COPD, asthma, and cystic fibrosis has increased at a significant pace. According to the National Health Profile 2015, over 3.5 million cases of acute respiratory infections were reported in 2014, reporting a spike of almost 30% since 2010.
Nebulizers are considered highly effective in the treatment of these conditions as they enable converting liquid medicine into aerosol, which can easily reach into the patient’s lungs when inhaled using an inhaler. Due to the benefits they provide in administering medication, these medical instruments are likely to get more popular in the coming years, thus boosting the India nebulizers market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving nebulizers market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10655
Escalating Population and Pollution to Boost Demand for Nebulizers across Metro Cities in India
The prevailing trends are indicative of the increasing incidence of COPD in metro cities such as Kolkata, Vijayawada, and Delhi. The condition is further aggravated through air pollution, vehicular pollution, escalating number of smokers, and the increasing population. Hence the demand for nebulizers is significantly higher in the metro cities of India.
Furthermore, the increasing investment to boost the healthcare infrastructure in India has paved way for aggressive research and development activities. “Technological advancements ensuring effective treatment for respiratory disorders will result in extensive usage of nebulizers in India,” said a lead TMR analyst. This will make India an opportunity-rich market for nebulizers.
The review presented here is based on information published by TMR in a report, titled “Nebulizers Market - India Industry Analysis, Size, Share, Growth, Trends, Volume and Forecast 2015 – 2023.”

Operating Room Equipment Market, Research Report, 2015 – 2023

The global operating room equipment market is dominated by five companies, including Stryker Corporation, GE Healthcare, and Siemens Healthcare. GE Healthcare, with a 19% share, is the clear leader in the global operating room equipment market. However, more than 40% of the market is taken up by regional players, which is illustrative of the way the global operating room equipment market is likely to progress in the coming years. The development of the fragmented global operating room equipment market has been determined largely by the ability of the players to innovate and improve existing products. In accordance with this, most industry leaders place heavy emphasis on establishing strong research and development facilities.
According to Transparency Market Research (TMR), the global operating room equipment market is expected to rise to US$42 bn by the end of 2023.
This 102 page report gives readers a comprehensive overview of the operating room equipment market. Browse through 6 data tables and 18 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/operating-room-equipment-market.html
Rising Utilization of Ambulatory Care Centers to Drive Demand for Operating Room Equipment
The prime driver for the global operating room equipment market is the rising demand for widespread availability of ambulatory care services. Ambulatory care centers deal with cases that need light to moderate attention and don’t require overnight hospitalization. The increasing prevalence of such cases and the rising preference for personal and home-based care and rehabilitation is likely to drive the demand for ambulatory care centers. This is likely to remain a strong positive influence on the global operating room equipment market.
The rising utilization of hybrid operating room systems in technologically advanced regions is another important driver for the global operating room equipment market. Hybrid operating rooms contain imaging equipment that complements the surgical equipment and allows surgeons to perform surgeries in minimally invasive fashion. The need for sophisticated and precisely engineered operating room equipment in hybrid operating rooms is likely to remain a key driver for the global operating room equipment market in the coming years.
The high cost of advanced operating room equipment has held the global operating room equipment market back, particularly in developing countries where the healthcare sector lacks significant government support. While private hospitals in major cities can afford to install advanced operating room equipment, the public healthcare sector remains underserved in several countries in Asia Pacific, Africa, and Latin America. The rising investment in the improvement of the healthcare sector in emerging countries could reverse the situation in the coming years, rejuvenating the growth prospects of the operating room equipment market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving operating room equipment market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1674
North America to Remain Dominant in Global Operating Room Equipment Market
Geographically, the global operating room equipment market is divided into North America, Europe, Asia Pacific, and Rest of the World. Of these, North America and Europe have traditionally led the global operating room equipment market, as the prosperity of countries in these regions has allowed for widespread installation of advanced medical devices. The dominance of these developed regions is expected to continue unabated through the 2015-2023 forecast period, with North America likely to account for more than 40% of the global operating room equipment market in 2023. The demand to consistently upgrade operating room equipment is likely to propel the operating room equipment market in developed regions in the coming years.
The key product segments in the operating room equipment market are biomedical systems, operating tables, endoscopes, operation room integration systems, surgical imaging displays, movable imaging systems, microscopes, anesthesia systems, operation room lights, and surgical booms. Of these, movable imaging systems dominate the global operating room equipment market and are likely to represent more than 25% of the market by 2023.
The above data is collated from a research report released by TMR, titled “Operating Room Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015-2023.”